Welcome, Guest Login | Signup | Portfolio | Bookmark | Contact
Markets

Symbol Name
Click for Symbol Help




Critical Outcome Technologies Inc. Announces COTI-2 Scientific Results Accepted for Presentation at Influential Scientific Conference

Marketwire.com - Oct 5, 2011

LONDON, ONTARIO--(Marketwire - Oct. 5, 2011) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that a scientific abstract about its lead oncology compound, COTI-2, has been accepted for presentation at the upcoming scientific conference, Discovery on Target: Emerging Targets for the Kinase Inhibitor Pipeline. The presentation entitled COTI-2: A highly effective and selective modulator of Akt/Akt2 protein levels and phospho-activation for the treatment of susceptible human cancers will be presented by Dr. Wayne Danter, COTI's CEO and CSO. This conference is being held November 2-4, 2011 in Boston, MA.

"The acceptance of our abstract indicates an eagerness on the part of the oncology community to learn more about our promising COTI-2 program," said Dr. Danter. "This upcoming presentation will afford us the opportunity to showcase to key influencers from many partnering organizations the science behind COTI-2, including the most recent data confirming that Akt/Akt2 are key cellular targets for COTI-2. It also serves as further validation for the ability of our proprietary artificial intelligence system, CHEMSASŪ, to generate important drug candidates."

COTI-2 is the most advanced compound in COTI's drug development pipeline and is the first to have been discovered by the CHEMSASŪ process. COTI-2's specific cellular targeting, low toxicity, and proven efficacy support a potentially dramatic change in the treatment of cancers that over express Akt/Akt2. Over expression of Akt/Akt2 is common in a broad range of human cancers, including ovarian, endometrial, pancreatic, breast, colorectal and lung. The percent of tumors with active Akt/Akt2 range from 20% to 100% depending on the cancer type.

About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge company specializing in accelerating the discovery of small molecules thus enabling these new drugs to be brought to market in a more cost effective, efficient and timely manner. COTI'S proprietary artificial intelligence system, CHEMSASŪ, utilizes a series of predictive computer models to identify compounds most likely to be successfully incorporated in disease-specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit www.criticaloutcome.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Critical Outcome Technologies Inc. (COTI)
Michael Barr
Vice President of Business Development and Marketing
519-858-5157
mbarr@criticaloutcome.com
www.criticaloutcome.com

Read Full Article from Marketwire.com

- Posted: 2011-10-05 08:16:40


 More Stock Investor Place Financial News  
Metals price rout is ending, says Credit Suisse
The Gold Rally is Far From Over ... CNBC.com Editorial
Uragold Raw Quartz Assays As High As 4N Purity (99.99% SiO2) Prior To Commencement Of Testing
Interview with Mr. Tony Green, CEO of UMINING Resources Inc.(UMNG)
Northern Gold Intersects 5.47 g/t Au OVER 17.3 m at Jonpol Deposit

 Stock Investor Place Financial News Archive
April 2016
March 2016
December 2014
August 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
May 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007















Featured Companies | My Place | News | Markets | Big Board | Blogs | Products & Services

Copyright 2024 Stock Investor Place Inc. All Rights Reserved.
Disclaimer - Terms of Use - Privacy Policy - Advertise